Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study.

ABSTRACT:

Background

The comparative effectiveness and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) has not been sufficiently evaluated in people with AIDS who initiate therapy.

Methods

The aim of the current study was to compare the effectiveness and tolerability of BIC/FTC/TAF with other first-line antiretroviral therapy (ART) regimens in treatment-naive adults from the CoRIS cohort who initiated ART with AIDS. Logistic regression models were used to estimate odds ratios (ORs) of association between initial regimen and achievement of viral suppression (VS), defined as human immunodeficiency virus RNA <50 copies/mL, and immunological recovery (IR), defined as CD4 count >200 cells/μL. Time to VS and the proportion of treatment discontinuations were als

SUBMITTER: Perez-Valero I 

PROVIDER: S-EPMC12596416 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature